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Alternative splicing is the main driver of protein diversity and allows the production of 
different proteins from each gene in the genome. Changes in exon exclusion, intron retention 
or the use of alternative splice sites can alter protein structure, localisation, regulation and 
function. In the heart, alternative splicing of sarcomeric genes, ion channels and cell 
signalling proteins can lead to cardiomyopathies, arrhythmias and other pathologies. Also, a 
number of inherited conditions and heart-related diseases develop as a result of mutations 
affecting splicing. Here we review the impact that changes in alternative splicing have on 
individual genes and on whole biological processes associated with heart disease. We also 
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Our knowledge of gene expression patterns in heart disease has increased over the years [1]. 
However, this information is largely incomplete, as it mainly relates to whole gene 
expression and does not take into account the variety of isoforms that are generated for each 
gene by alternative splicing (AS). Considering that most human genes are alternatively 
spliced and thus generate alternative isoforms with different functional and/or structural 
properties [2,3], the reality is that our knowledge of the molecular mechanisms that mediate 
heart disease is still very limited. Here we review the impact that AS has on heart 
development, homeostasis and disease and we discuss the manipulation of AS as a promising 
therapy for heart disease. 
 
RNA Splicing and Alternative Splicing 
RNA splicing is the molecular process by which introns are removed from immature pre-
mRNAs and exons are linked together. Splicing is carried out by a large ribonucleoprotein 
complex, called the spliceosome. It is comprised of more than 100 core proteins and five 
small nuclear RNAs (snRNAs U1, U2, U4, U5 and U6), each of which interacts with a 
number of proteins to form small nuclear ribonucleoprotein particles (snRNP) [4-6]. The core 
splicing signal in the mRNA includes three elements that are present in every intron: the 5' 
splice site (which includes the GU nucleotides), the 3' splice site (which includes the AG 
nucleotides and the polypyrimidine tract) and the branch point sequence [4]. Splicing is not a 
rigid process. Very often variation in the final combination of exons and introns in the mature 
mRNAs occur (Fig. 1). This variation is due to alternative splicing (AS) and has a main role 
in mRNA stability, localisation and the generation of functional and structural protein 
diversity. AS allows the production of proteins with different function, structure, localisation 
and regulation, all from a single gene. It is considered that around 86% of all genes are 
alternatively spliced and that there are, on average, at least seven AS events per multi-exon 
gene in humans [2,7]. Genes tend to express many isoforms simultaneously [8], of which 
70% encode important functional or structural changes for the protein [3]. Importantly, it was 
recently unveiled that AS is one of the major forces driving evolution and shaping species-
specific features [9,10]. 
 
Alternative Splicing Regulation 
Regulation of alternative splicing is not only mediated by the core splicing signal, but also by 
additional elements. Auxiliary cis-regulatory sequences found in exons and neighbouring 
introns can either facilitate recruitment of the spliceosome and inclusion of an exon in the 
mature mRNA (splicing enhancer) or they can prevent spliceosome assembly and cause 
skipping of the exon (splicing silencer) [4,5]. Splicing enhancers are known as ESE or ISE 
and splicing silencers are known as ESS or ISS, depending on whether they work from an 
exonic or an intronic location, respectively [4,5]. Whereas enhancer elements are thought to 
participate mainly in constitutive splicing, silencers have a predominant role in AS [4]. The 
activity of cis-regulatory sequences can be context-dependent, changing their function when 
moved to a different gene or region [4].  Pre-mRNAs carry several sequences that can act as 
potential enhancers or silencers, but only a few of them will be associated with regulatory 
proteins.  
Most auxiliary cis-regulatory sequences act by recruiting trans-regulatory factors 
(Fig. 2). These RNA-binding proteins orchestrate the AS of whole transcript networks in a 
biologically-coherent manner [11]. Traditionally, it was considered that exonic enhancers 
bind SR proteins (Ser/Arg-rich), which facilitate spliceosome assembly, while silencers 
recruit proteins of the hnRNP family to interfere with spliceosome formation and exon 
inclusion. On the other hand, intronic enhancers bind hnRNPL, RBFOX1, RBFOX2, 
RBFOX3 and NOVA, whereas silencers recruit hnRNPL, PTB and hnRNPA1, among others 
[4]. However, it is becoming increasingly clear that the same trans-regulatory factor can act 
as an enhancer or a silencer depending on its position and context [12-16]. In addition, many 
trans-regulatory factors act as antagonistic pairs. For instance, the balance between CUG-
binding protein (CUGBP) and ETR-like factors (CELF) and PTB regulates exon inclusion or 
exclusion [17]. 
Mechanistically, SR proteins initiate spliceosome recruitment by simultaneously 
binding to an ESE in the mRNA and to the U1 snRNP, allowing interaction of U1 with the 5’ 
splice site in the intron [6,15]. This process is modulated by phosphorylation of the SR 
protein and represents the first step in the assembly of the rest of the spliceosome, as 
reviewed elsewhere [6]. Although the molecular mechanism underlying exon skipping is less 
well understood, it has been recently shown that hnRNP proteins can inhibit exon inclusion 
by changing the way U1 binds to the exon, which prevents exchange of U1 for U6 and thus 
precludes the splicing catalytic process [18]. Although SR proteins and hnRNPs are widely 
expressed, changes in their stoichiometry can mediate tissue-specific AS differences [11]. 
In addition to direct regulatory factors, it should also be taken into account that 
splicing takes place as the mRNA is being transcribed and is affected by processes regulating 
transcription. In this context, it was recently shown that histone modifications affect the 
recruitment of trans-regulatory factors and therefore the splicing outcome [19]. The precise 
balance of regulatory proteins in a cell and cis-regulatory elements in a gene, together with 
the length of exons and flanking introns, the pre-mRNA secondary structure and epigenetic 
cues, contribute to determine the splicing pattern [4,11,20].  
The interplay between different trans-regulatory splicing factors controls whole 
biological processes. For instance, in parallel with the changes in gene expression taking 
place in the postnatal heart, several proteins switch their isoforms by AS after birth to meet 
the increased contraction demands. This switch is mediated by the balanced action of 
muscleblind-like (MBNL), RBFOX and CELF trans-regulatory factors, together with 
microRNAs that control the activity of these factors [21,22]. While CELF proteins decrease 
during cardiac development, MBNL increases. Manipulation of CELF and MBNL expression 
in the adult heart to replicate their levels in the embryo results in reactivation of the 
embryonic splicing pattern [21]. A transcriptome-wide analysis of AS in a mouse model of 
aortic stenosis suggested a common splicing regulatory programme in the embryonic and 
diseased hearts [23]. Myocardial expression of many trans-regulatory factors changes in heart 
failure, both in human patients and in mouse models, following a general downregulation of 
splicing-related factors [24,25]. Analysis of cis-regulatory motifs in alternatively spliced 
exons in heart failure patients showed an enrichment in hnRNPF and MBNL binding motifs 
together with a downregulation of hnRNPF expression itself [24]. In mouse models of 
myocardial infarction and aortic stenosis, a decline in RBFOX1 has also been reported 
[23,25]. However the functional implications of these changes and the regulatory 
mechanisms that control expression of trans-regulatory factors in heart disease are not well 
understood. It should be also noted that trans-regulatory factors are often regulated by AS 
themselves, although again the implications for heart disease are unclear. 
 
Alternative Cardiac Contraction and Relaxation 
Alterations in sarcomeric gene splicing were among the first to be associated with acquired 
and inherited heart disease (Fig. 3). A recent survey using exon microarrays showed AS of 
cardiac troponins T and I, -myosin heavy chain and filamin C in ischemic cardiomyopathy 
patients [24]. In thin filaments, a mutation in the 5’ splice donor site in intron 15 of the 
human cardiac troponin T gene (TNNT2) results in protein truncation and is associated with 
hypertrophic cardiomyopathy [26,27]. Overexpression of this protein in transgenic mice 
induces myocellular disarray and diastolic dysfunction, together with a reduction in 
cardiomyocyte size and number [28]. AS also controls the transition between embryonic and 
adult cardiac troponin T isoforms [29]. The switch between both isoforms results from exon 5 
exclusion, and is regulated by the trans-regulatory factors MBNL1 and CUGBP2, together 
with SRSF1 [30-32]. Tropomyosin (TPM) is also subjected to AS, which allows generation 
of several variants for each of the four tropomyosin genes often in a cell type-specific manner 
[33]. In the heart, AS of exon 2b in TPM1 produces a variant associated with human dilated 
cardiomyopathy (DCM) and heart failure [34]. Mice overexpressing this isoform in the heart 
show impaired cardiac function, decreased myofilament Ca
2+
 sensitivity and DCM [34]. 
AS also has functional effects on thick filament proteins. Mutations in different splice 
sites in myosin binding protein C (MyBP-C) promote exon skipping and are associated with 
hypertrophic cardiomyopathy [35,36]. A net reduction of full-length MyBP-C expression is 
observed in tissue homogenates, suggesting that splice site mutations cause MyBP-C 
haploinsufficiency that would be the source of the condition [37]. Also, in the M-band of the 
sarcomere, an alternatively spliced version of EH-myomesin has been described as a marker 
of heart failure. This isoform, which is abundant in the embryonic heart, is strongly induced 
in DCM patients and decreases after mechanical unloading with LVAD [38]. 
Different protein isoforms of varying sizes are generated from the titin gene by AS of 
some of its 363 exons. The expression of titin isoforms is developmentally regulated, with 
larger isoforms found in the developing heart. As the heart matures, they are substituted by 
smaller isoforms with lower abundance of immunoglobulin and PEVK-rich domains [39]. 
The reduction in the number of these spring-like elements results in increased passive 
stiffness. A shift towards expression of the larger more-compliant titin isoforms in the adult 
heart reduces passive stiffness and is associated with DCM [40]. Interestingly, about a third 
of the titin mutations found in patients with familial DCM affect splicing [41]. These 
mutations cause exon skipping, intron retention and other splicing alterations that result in 
truncated titin isoforms and DCM. Titin splicing is regulated, at least in part, by the RNA-
binding motif protein 20 (RBM20). RBM20 is preferentially expressed in the heart and 
controls AS of genes involved in different processes. Lack of RBM20 in rat results in 
aberrant titin splicing, cardiac fibrosis, arrhythmias, diastolic dysfunction and DCM, which 
mirrors the phenotype observed in humans carrying RBM20 mutations [42]. Remarkably, 
mutations in the Arg/Ser-rich (RS) domain of RBM20 have been associated with 2-3% of all 
idiopathic DCM cases and up to 13% of cases with cardiac sudden death [43]. 
RBM20 is also responsible for alternative splicing of LIM-binding protein 3 
(LDB3/ZASP/Cypher). Like other enigma proteins, LDB3 is located in the Z-disc and helps 
maintain the sarcomeric structure. Loss of RBM20 function results in exclusion of exon 4 
from the mature LDB3 mRNA [42]. This exon encodes the protein domain that recruits the 
glycolytic enzyme phosphoglucomutase 1 (PGM1) to the sarcomere under stress conditions 
and impairment of this interaction is associated with DCM [44]. Similarly, aberrant splicing 
of other enigma proteins is also associated with heart disease. The splicing pattern of Enigma 
homologue (ENH) changes during heart development and in response to stress. Whereas 
some isoforms seem to be cardioprotective, others are sufficient to promote cardiomyocyte 
hypertrophy, at least in vitro [45]. 
 
Alternative Cell Signalling 
Insulin-like growth factor (IGF-1) is an illustrative example of functional changes 
orchestrated by AS. IGF-1 diversity is provided at the N-terminal end of the protein by two 
alternative promoters that stimulate transcription either from exon 1 or from exon 2, and at 
the C-terminal end by AS of exons 5 and 6, which encode alternative E-peptides. The 
different E-peptides interact with the extracellular matrix with different affinity and 
determine IGF-1 bioavailability [46]. Cardiomyocyte expression of an IGF-1 isoform 
carrying the Ea peptide (IGF-1Ea) promotes cardiac regeneration following myocardial 
infarction [47]. IGF-1Ea activates mobilization of endothelial progenitors from the bone 
marrow to improve vascularisation of the infarct border region [48]. In addition, it reduces 
oxidative stress and improves cardiac function in a mouse model of DCM [49,50]. In skeletal 
muscle, IGF-1Ea promotes regeneration and induces expression of the calcineurin splicing 
variant CnAβ1, which recapitulates the regenerative effects of IGF-1Ea [51,52]. CnAβ1 
contains a unique C-terminal domain that is not present in any other known protein. This 
unique domain is the result of intron 12-13 retention and allows CnAβ1 to interact with the 
mTORC2 complex and activate the Akt signalling pathway [25]. In contrast with other 
calcineurin isoforms, which promote pathological cardiac hypertrophy by activating the 
transcription factor NFAT [53], CnAβ1 has a beneficial effect on the heart. Overexpression 
of this isoform improves function after myocardial infarction, reducing scar size and fibrosis 
[25]. 
Like IGF-1, the biological activity of vascular endothelial growth factor (VEGF) is 
strongly conditioned by AS. Several different isoforms are generated from a single VEGFA 
gene depending on how exons 6, 7 and 8 are spliced [54]. Alternative usage of two different 
splice sites in exon 8 produces two different proteins, differing in just six amino acids, that 
are either pro-angiogenic or anti-angiogenic depending on whether the proximal or distal 
splice site is used, respectively. Exons 6 and 7 define the ability of VEGF-A to bind heparin 
and determine the spatial distribution of the molecule. Isoforms lacking exons 6 and 7 are 
freely diffusible and knockout mice for these exons show defects in vessel growth and 
capillary branching [55].  
VEGF partly promotes endothelial cell growth and angiogenesis by activating splicing 
of the transcription factor X-box binding protein 1 (XBP1), a mediator of the unfolded 
protein response (UPR) [56]. The UPR is activated in infarcted hearts and in heart failure in 
response to ER stress, and is in part mediated by XBP1 [57]. XBP1 splicing is not carried out 
by the spliceosome but by IRE1, a Ser/Thr kinase with RNAse activity that is activated in 
response to stress. To produce the active XBP1 form (XBP1s), IRE1 removes a short intron 
in the XBP1 mRNA. This promotes a shift in the reading frame that results in expression of a 
transcription activation domain at the C-terminal end of the protein [58]. XBP1s induces the 
B-type natriuretic peptide (BNP) in response to cardiomyocyte stress [59]. BNP is produced 
by cardiac myocytes to promote diuresis and vascular relaxation in an attempt to reduce fluid 
retention and blood pressure, and is widely used as a marker of heart failure. An AS isoform 
of BNP that retains intron 2 was identified in heart failure patients [60]. This isoform lacks 
the vasorelaxing activity of BNP but retains its diuretic effect on the kidneys. Expression of 
this variant is around 100x lower than the main BNP isoform and decreases after mechanical 
unloading with LVAD. Whereas XBP1 splicing can have beneficial effects on the 
cardiovascular system, sustained XBP1s expression in endothelial cells induces autophagy 
and atherosclerosis [61]. 
An AS isoform of the serum response factor (SRF), a transcription factor that controls 
a variety of cellular processes, has been associated with heart failure [62]. This isoform has 
little transcription activation capacity and acts as a dominant negative. The SRF coactivator 
myocardin is regulated by AS in a tissue-specific manner [63]. Its cardiac form carries a 
unique peptide in the N-terminal domain that allows it to interact with the transcription factor 
MEF2 and regulate its transcriptional activity. MEF2 is also differentially spliced in different 
tissues and developmental stages [64], although the impact on heart disease is still unclear. 
AS modulates the function of T-box transcription factors (TBX), which are involved 
in different aspects of heart development [65]. Two TBX5 isoforms are produced in the heart 
by AS. The longer isoform (TBX5a) is one of the main regulators of cardiac lineage 
specification and heart development. Inclusion of exon 8 in TBX5 by AS introduces a 
premature stop codon and results in a truncated protein with no transcriptional activity 
(TBX5b) [66]. Whereas there’s strong TBX5a expression during cardiac development, 
TBX5b is the predominant form in the adult heart. Overexpression of TBX5a in the adult 
heart using transgenic mice induces cardiac hypertrophy, whereas TBX5b promotes growth 
arrest, at least in C2C12 myoblasts [66]. TBX5 interacts with the trans-regulatory splicing 
factor SRSF2 to modulate AS [67]. Certain mutations affecting the capacity of TBX5 to 
regulate splicing are associated with Holt-Oram syndrome, which is characterised by limb 
malformations and heart septation defects. Other TBX5 mutations with less cardiac 
penetrance do not affect this activity. This suggests that modulation of AS by TBX5 may be 
necessary for correct heart development. AS of TBX20 and TBX3 has also been detected in 
the heart, however the functional implications of the different isoforms are yet to be 
determined. 
 
Alternative Ion Channels, Calcium Handling and Arrhythmias 
Calcium entry through the cell membrane is regulated by voltage-dependent L-type calcium 
channels composed of 1 (pore), 2/,  and  subunits. In the heart, the main 1 subunit 
(CaV1.2) undergoes AS in various exons both during development and in heart failure [68]. 
Cardiac and smooth muscle express distinct CaV1.2 isoforms that have different sensitivity to 
dihydropyridine calcium channel blockers [68,69]. Mutations of CaV1.2 in Timothy 
syndrome, a multisystem disease characterised by cardiac arrhythmias, autism and other 
symptoms, have different functional impact depending on whether AS of the mutually 
exclusive exons 8 and 8a takes place [70]. AS of this exon in CaV1.2 is regulated by PTB and 
also partially by RBM20 [42,71]. 
Calcium handling in the sarcoplasmic reticulum is regulated by AS of the calcium 
ATPase 2 (SERCA2) and the ryanodine receptor (RyR) mRNAs (Fig. 3). RyRs facilitate 
calcium release from the sarcoplasmic reticulum to induce muscle contraction. The three RyR 
genes comprise more than 100 exons and generate several isoforms that are differentially 
regulated by AS in the embryonic and adult hearts. Two splicing variants of the cardiac RyR 
(RyR2) carrying 24 bp or 30 bp insertions show distinct cellular localization and modulation 
of calcium release [72]. RyR splicing is regulated, at least in part, by SRSF2. Induction of 
this trans-regulatory factor has been proposed to be a compensatory mechanism in aortic 
stenosis patients with cardiac hypertrophy [73]. Knockout mice for SRSF2 show reduced 
RyR expression and develop DCM [74]. Sarcoplasmic calcium release is also affected by 
triadin mRNA splicing, which is regulated by SRSF10 and RBM20 [42,75]. SRSF10 
knockout mice show reduced expression of triadin and calsequestrin 2 that results in calcium 
handling defects and embryonic lethality [75]. Calcium is pumped back into the sarcoplasmic 
reticulum by SERCA2 to allow muscle relaxation. Expression of the SERCA2a isoform in 
cardiac and slow skeletal muscle is regulated by AS. Disruption of SERCA2 splicing in 
knockout mice results in a switch from SERCA2a to SERCA2b, a non-muscle isoform 
present in other cell types. These mice show reduced calcium uptake, impaired contractility 
and relaxation, developmental cardiac defects and mild concentric hypertrophy [76]. 
The calcium/calmodulin-regulated kinase II (CaMKII) phosphorylates different 
calcium-handling proteins, including the SERCA regulator phospholamban. CaMKII 
undergoes a postnatal isoform switch mediated by the trans-regulatory factors SRSF1 and 
RBM20 [32,42]. Loss of either of these factors results in exclusion of exon 14, which 
encodes a nuclear localisation signal, and mislocalisation of the protein. SRSF1 knockout 
mice show severe excitation-contraction coupling defects, cardiac fibrosis and death at 6-8 
weeks of age. Transgenic expression of the alternatively spliced CaMKII in cardiomyocytes 
phenocopies these defects, suggesting that AS of this kinase is responsible for the phenotype 
observed in SRSF1 knockout mice. 
Sodium and potassium channels are also subjected to AS. Heart failure patients show 
increased expression of C-terminal truncated isoforms of the sodium channel SCN5A [77]. 
SCN5A splicing is altered in these patients by an increase in the splicing regulators RBM25 
and LUC7L3. They favour the production of a truncated isoform and a reduction in the full-
length protein, resulting in a strongly decreased Na
+
 current [78]. Mutations affecting SCN5A 
splicing in humans are associated with ventricular fibrillation [79]. Similarly, mutations in the 
potassium channels KCNH2 and KCNQ2 cause intron retention and exon exclusion, 
respectively, and are associated with long QT syndrome [80,81]. Besides channels 
themselves, AS of the K
+
 channel interacting protein 2 (KChIP2) generates two splicing 
variants that modulate the outward K
+
 current of Kv4.3 channel [82]. 
 
Alternative Splicing Associated Disorders 
Several disease-causing mutations are estimated to affect splicing and directly or indirectly 
alter either regulatory sequences or trans-regulatory factors [83]. Myotonic dystrophy (DM) 
is probably the main example of an inheritable disease caused by aberrant splicing regulation. 
DM patients show progressive muscle wasting, muscle hypercontractility, cardiac conduction 
defects, insulin resistance and cardiomyopathy, among other symptoms. DM type 1 (DM1) is 
caused by an accumulation of a CTG repeat in the 3’ untranslated region of the DM protein 
kinase (DMPK) gene, whereas DM type 2 is caused by a CCTG expansion in the zinc finger 
protein 9 (ZNF9) gene [84,85]. Aberrant repetition of these motives does not affect the 
proteins encoded by these genes but instead affects the splicing factors that bind these 
motives in their mRNAs. The CTG (CUG in the mRNA) expansion results in sequestration of 
MBNL1 and increased expression of CUGBP1. Transgenic mouse models carrying the CTG 
expansion in DMPK, lacking MBNL1 or overexpressing CUGBP1 display a similar 
phenotype to that observed in DM1 patients [86-88]. These mice showed that increased 
expression of CUGBP1 in DM1 is due to its hyperphosphorylation and stabilization by PKC 
[89]. Inhibition of PKC was able to improve cardiac function in these mice although it did not 
reduce mortality [90]. The imbalance of CUGBP1 and MBNL1 disrupts AS of other cellular 
mRNA targets, including cardiac troponin T, the insulin receptor or the chloride channel 
Clcn1, and results in muscle dystrophy, insulin resistance and myotonia [84,91-93]. In 
addition to splicing alterations, the toxic DMPK mRNA induces expression of the 
transcription factor NKX2.5, resulting in a decrease in connexin 43 and cardiac conduction 
defects [94].  
 The Hutchinson-Gilford progeria syndrome (HGPS) is another major example of a 
disease associated with splicing defects. Progeria patients show premature ageing and 
progressively develop atherosclerosis in their coronary and cerebral arteries that eventually 
causes their death. Progeria is caused by mutations in the gene encoding the nuclear envelope 
protein lamin A (LMNA) [95]. A single base mutation in exon 11 of the LMNA gene 
activates a cryptic splice site. This causes alternative splicing of the mRNA and production of 
a truncated protein (called progerin) with a 50 amino acid deletion in the C-terminal domain. 
These amino acids are necessary for the processing of prelamin A into lamin A by the 
protease ZMPSTE24 and for translocation of lamin A to the nuclear lamina [96]. Expression 
of progerin results in structural defects in the nuclear envelope and affects cell division and 
chromatin organisation. AS of exon 11 is controlled by SRSF1 and SRSF6. Whereas 
inhibition of SRSF1 enhances correct splicing of the lamin A mRNA, downregulation of 
SRSF6 promotes progerin expression [97]. Interestingly, progerin is also expressed at low 
levels in healthy individuals and its expression increases with ageing [98]. Telomere 
shortening promotes AS of lamin A and several other genes that may also contribute to 
cellular senescence and ageing [99]. Modulation of lamin A splicing with an antisense 
oligonucleotide in a progeria mouse model has shown promising results [100]. 
 
Alternative Splicing-based Therapeutics 
Besides the use of specific splicing isoforms for the treatment of heart disease, as explained 
above for IGF-1Ea and CnAβ1 [25,47], AS can be manipulated using small modified 
antisense oligonucleotides (AONs) [xref antisense therapeutics in this JCTR issue]. These 
oligonucleotides carry an antisense sequence that binds to a splicing regulatory sequence in 
the target exon, interfering with splicing and preventing incorporation of the exon into the 
final transcript (Fig 4). AONs carry chemical modifications in their backbone that makes 
them more stable, increases their target selectivity and makes the RNA-RNA interaction 
resistant to cleavage by RNAse H [101].  
In a DM1 mouse model, a morpholino oligonucleotide targeting the CTG repeat 
prevents MBNL1 sequestration, corrects splicing, reduces the effects of the toxic mRNA and 
improves the disease symptoms [102,103]. A similar approach has been used for the 
treatment of Duchenne muscular dystrophy (DMD), in which several mutations in the 
dystrophin gene cause premature truncation of the protein. Skipping of certain exons using 
AONs can restore the open reading frame, generating a partially active protein [104]. Cardiac 
delivery of AONs has proven challenging, but new biochemical modifications in the 
oligonucleotides have improved splicing of the mutated dystrophin exons in the heart [105]. 
In fact, DMD is the disease for which an AON therapy is closest to application in humans 
[106]. In addition to AONs, skipping of the mutated dystrophin exons has been achieved in 
small and large animal models using gene therapy. An adeno-associated viral vector 
expressing a modified U7 small nuclear RNA targets specific cis-regulatory sequences in the 
dystrophin mRNA, promotes exon skipping and improves expression of a functional 
dystrophin protein [107]. 
AONs have also been used to treat progeria in animal models. An AON designed to 
block the binding of the splicing machinery to the mutant splice site in prelamin A favours 
expression of the full-length protein and ameliorates the progeria phenotype [100,108]. 
Another disease for which AONs are being developed is spinal muscular atrophy, which is 
associated with arrhythmias and other cardiac defects, among other symptoms. This disease is 
caused by mutations in the spinal motor neuron 1 gene (SMN1) that result in loss of function 
of the protein and motor neuron disease. AON therapy to promote inclusion of exon 7 in the 
second SMN gene (SMN2) produces a functional SMN protein that partially compensates the 
loss of SMN1 [109]. These encouraging results observed in animal models have prompted a 
number of clinical trials using AONs to treat different diseases, including muscle dystrophies, 
progeria and spinal muscular atrophy [110]. Beside the treatment of inherited conditions, 
AONs have been used to correct splicing in other diseases like cancer [111,112]. In addition, 
AONs have been used to model human disease in mice [113]. 
 
Future Perspectives 
Our knowledge of the involvement of individual splicing isoforms in heart disease has 
increased over the years; however we still lack an understanding of how global alternative 
splicing patterns are regulated. The advent of next-generation sequencing has paved the way 
to a more comprehensive view of transcriptome-wide changes and some general splicing 
patterns are beginning to emerge. Potential applications include the detection of novel splice 
sites and cis-regulatory elements, as well as the analysis of relative isoform abundances and 
alternative exon usage. Despite the variety of bioinformatics methods available, 
computational analysis of AS remains however challenging and demands the development of 
new ad hoc strategies and standardised protocols.  Another major objective in the field is to 
determine how many of the alternative isoforms generated for each mRNA are actually 
translated into proteins. In addition, it needs to be determined whether the splicing changes 
observed in heart disease, besides genetic mutations, are actually a cause or a consequence of 
the condition and whether they are actually detrimental. Currently there’s no answer to these 
questions and thus the exact impact of AS on heart disease remains to be determined. On the 
bright side, manipulation of AS using antisense oligonucleotides or the use of specific 
splicing isoforms for the treatment of muscular and heart diseases is progressing fast and 
providing encouraging results.   
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Alternative splicing is the main mechanism driving protein diversity and allows expression of 
different proteins from each gene. We are slowly beginning to unveil the complexity of post-
transcriptional regulation in the diseased heart. Alternative splicing can change protein 
structure, localisation, regulation and function, leading to cardiomyopathies, arrhythmias and 
other pathologies. Identifying a protein that is differentially expressed in a pathological 
condition is not sufficient; it is essential to identify the version (isoform) of such protein, 
which may have particular features. It is also important to understand how alternative splicing 
is regulated in a global manner, so that potential therapeutic targets can be unveiled. 
Alternative splicing modulation using antisense oligonucleotides has recently emerged as a 




1. Lara-Pezzi E, Dopazo A, Manzanares M (2012) Understanding cardiovascular disease: a 
journey through the genome (and what we found there). Dis Model Mech 5:434-443. 
2. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth 
GP et al (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 
456:470-476. 
3. Rodriguez JM, Maietta P, Ezkurdia I, Pietrelli A, Wesselink J-J, Lopez G, Valencia A, 
Tress ML (2013) APPRIS: annotation of principal and alternative splice isoforms. Nucl Acid 
Res 41:D110-D117. 
4. Wang Z, Burge CB (2008) Splicing regulation: from a parts list of regulatory elements to 
an integrated splicing code. RNA 14:802-813. 
5. House AE, Lynch KW (2008) Regulation of alternative splicing: more than just the ABCs. 
J Biol Chem 283:1217-1221. 
6. Wahl MC, Will CL, Lührmann R (2009) The Spliceosome: design principles of a dynamic 
RNP machine. Cell 136:701-718. 
7. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative 
splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 
40:1413-1415. 
8. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J 
et al (2012) Landscape of transcription in human cells. Nature 489:101-108. 
9. Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, Lee LJ, Slobodeniuc V, 
Kutter C et al (2012) The evolutionary landscape of alternative splicing in vertebrate species. 
Science 338:1587-1593. 
10. Merkin J, Russell C, Chen P, Burge CB (2012) Evolutionary dynamics of gene and 
isoform regulation in Mammalian tissues. Science 338:1593-1599. 
11. Licatalosi DD, Darnell RB (2010) RNA processing and its regulation: global insights into 
biological networks. Nat Rev Genet 11:75-87. 
12. Sun S, Zhang Z, Fregoso O, Krainer AR (2012) Mechanisms of activation and repression 
by the alternative splicing factors RBFOX1/2. RNA 18:274-283. 
13. Zhang C, Frias MA, Mele A, Ruggiu M, Eom T, Marney CB, Wang H, Licatalosi DD et 
al (2010) Integrative modeling defines the Nova splicing-regulatory network and its 
combinatorial controls. Science 329:439-443. 
14. Wang E, Cody N, Jog S, Biancolella M, Wang T, Treacy D, Luo S, Schroth G et al 
(2012) Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by 
muscleblind proteins. Cell 150:710-724. 
15. Cho S, Hoang A, Sinha R, Zhong X-Y, Fu X-D, Krainer AR, Ghosh G (2011) Interaction 
between the RNA binding domains of Ser-Arg splicing factor 1 and U1-70K snRNP protein 
determines early spliceosome assembly. Proc Natl Acad Sci USA 108:8233-8238. 
16. Braunschweig U, Gueroussov S, Plocik AM, Graveley Brenton r, Blencowe Benjamin j 
(2013) Dynamic integration of splicing within gene regulatory pathways. Cell 152:1252-
1269. 
17. Charlet-B N, Logan P, Singh G, Cooper TA (2002) Dynamic antagonism between ETR-3 
and PTB regulates cell type-specific alternative splicing. Mol Cell 9:649-658. 
18. Chiou N-T, Shankarling G, Lynch Kristen w (2013) hnRNP L and hnRNP A1 induce 
extended U1 snRNA interactions with an exon to repress spliceosome assembly. Mol Cell 
49:972-982. 
19. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T (2010) 
Regulation of alternative splicing by histone modifications. Science 327:996-1000. 
20. Barash Y, Calarco JA, Gao W, Pan Q, Wang X, Shai O, Blencowe BJ, Frey BJ (2010) 
Deciphering the splicing code. Nature 465:53-59. 
21. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA (2008) A 
postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the 
developing heart. Proc Natl Acad Sci USA 105:20333-20338. 
22. Kalsotra A, Wang K, Li P-F, Cooper TA (2010) MicroRNAs coordinate an alternative 
splicing network during mouse postnatal heart development. Genes & Development 24:653-
658. 
23. Park JY, Li W, Zheng D, Zhai P, Zhao Y, Matsuda T, Vatner SF, Sadoshima J et al 
(2011) Comparative analysis of mRNA isoform expression in cardiac hypertrophy and 
development reveals multiple post-transcriptional regulatory modules. PLoS ONE 6:e22391. 
24. Kong SW, Hu YW, Ho JWK, Ikeda S, Polster S, John R, Hall JL, Bisping E et al (2010) 
Heart failure-associated changes in RNA splicing of sarcomere genes. Circ Cardiovasc Genet 
3:138-146. 
25. Felkin LE, Narita T, Germack R, Shintani Y, Takahashi K, Sarathchandra P, López-
Olañeta MM, Gómez-Salinero JM et al (2011) Calcineurin splicing variant CnAβ1 improves 
cardiac function after myocardial infarction without inducing hypertrophy. Circulation 
123:2838-2847. 
26. Thierfelder L, Watkins H, Macrae C, Lamas R, Mckenna W, Vosberg H-P, Seldman JG, 
Seidman CE (1994) α-tropomyosin and cardiac troponin T mutations cause familial 
hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77:701-712. 
27. Watkins H, Mckenna WJ, Thierfelder L, Suk HJ, Anan R, O'donoghue A, Spirito P, 
Matsumori A et al (1995) Mutations in the genes for cardiac troponin T and alpha-
tropomyosin in hypertrophic cardiomyopathy. New England Journal of Medicine 332:1058-
1065. 
28. Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL, Schwartz S, 
Robbins J et al (1998) A truncated cardiac troponin T molecule in transgenic mice suggests 
multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 
101:2800-2811. 
29. Ta C, Cp O (1984) A single troponin T gene regulated by different programs in cardiac 
and skeletal muscle development. Science 226:979-982. 
30. Warf MB, Diegel JV, Von Hippel PH, Berglund JA (2009) The protein factors MBNL1 
and U2AF65 bind alternative RNA structures to regulate splicing. Proc Natl Acad Sci USA 
106:9203-9208. 
31. Goo Y-H, Cooper TA (2009) CUGBP2 directly interacts with U2 17S snRNP 
components and promotes U2 snRNA binding to cardiac troponin T pre-mRNA. Nucl Acid 
Res 37:4275-4286. 
32. Xu X, Yang D, Ding JH, Wang W, Chu PH, Dalton ND, Wang HY, Jr JRB et al (2005) 
ASF/SF2-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-
contraction coupling in cardiac muscle. Cell 120:59-72. 
33. Gunning PW, Schevzov G, Kee AJ, Hardeman EC (2005) Tropomyosin isoforms: 
divining rods for actin cytoskeleton function. Trends Cell Biol 15:333-341. 
34. Rajan S, Jagatheesan G, Karam CN, Alves ML, Bodi I, Schwartz A, Bulcao CF, D'souza 
KM et al (2010) Molecular and functional characterization of a novel cardiac-specific human 
tropomyosin isoform. Circulation 121:410-418. 
35. Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, Gautel M, Labeit S et 
al (1995) Cardiac myosin binding protein-C gene splice acceptor site mutation is associated 
with familial hypertrophic cardiomyopathy. Nat Genet 11:438-440. 
36. Watkins H, Conner D, Thierfelder L, Jarcho JA, Macrae C, Mckenna WJ, Maron BJ, 
Seidman JG et al (1995) Mutations in the cardiac myosin binding protein-C gene on 
chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 11:434-437. 
37. Marston S, Copeland ON, Jacques A, Livesey K, Tsang V, Mckenna WJ, Jalilzadeh S, 
Carballo S et al (2009) Evidence from human myectomy samples that MYBPC3 mutations 
cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 105:219-222. 
38. Schoenauer R, Emmert M, Felley A, Ehler E, Brokopp C, Weber B, Nemir M, Faggian G 
et al (2011) EH-myomesin splice isoform is a novel marker for dilated cardiomyopathy. 
Basic Res Cardiol 106:233-247. 
39. Lahmers S, Wu Y, Call DR, Labeit S, Granzier H (2004) Developmental control of titin 
isoform expression and passive stiffness in fetal and neonatal myocardium. Circ Res 94:505-
513. 
40. Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, Del Monte F, 
Hajjar RJ et al (2004) Passive stiffness changes caused by upregulation of compliant titin 
isoforms in human dilated cardiomyopathy hearts. Circ Res 95:708-716. 
41. Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D, Conner L, 
Depalma SR et al (2012) Truncations of titin causing dilated cardiomyopathy. N Engl J Med 
366:619-628. 
42. Guo W, Schafer S, Greaser ML, Radke MH, Liss M, Govindarajan T, Maatz H, Schulz H 
et al (2012) RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med 
18:766-773. 
43. Brauch KM, Karst ML, Herron KJ, De Andrade M, Pellikka PA, Rodeheffer RJ, Michels 
VV, Olson TM (2009) Mutations in ribonucleic acid binding protein gene cause familial 
dilated cardiomyopathy. J Am Coll Cardiol 54:930-941. 
44. Arimura T, Inagaki N, Hayashi T, Shichi D, Sato A, Hinohara K, Vatta M, Towbin JA et 
al (2009) Impaired binding of ZASP/Cypher with phosphoglucomutase 1 is associated with 
dilated cardiomyopathy. Cardiovasc Res 83:80-88. 
45. Yamazaki T, Wälchli S, Fujita T, Ryser S, Hoshijima M, Schlegel W, Kuroda SI, 
Maturana AD (2010) Splice variants of Enigma homolog, differentially expressed during 
heart development, promote or prevent hypertrophy. Cardiovasc Res 86:374-382. 
46. Hede MS, Salimova E, Piszczek A, Perlas E, Winn N, Nastasi T, Rosenthal N (2012) E-
peptides control bioavailability of IGF-1. PLoS ONE 7:e51152. 
47. Santini MP, Tsao L, Monassier L, Theodoropoulos C, Carter J, Lara-Pezzi E, Slonimsky 
E, Salimova E et al (2007) Enhanced regeneration of the mammalian heart. Circ Res 
100:1732-1740. 
48. Santini MP, Lexow J, Borsellino G, Slonimski E, Zarrinpashneh E, Poggioli T, Rosenthal 
N (2011) IGF-1Ea induces vessel formation after injury and mediates bone marrow and heart 
cross-talk through the expression of specific cytokines. Biochem Biophys Res Commun 
410:201-207. 
49. Vinciguerra M, Santini MP, Martinez C, Pazienza V, Claycomb WC, Giuliani A, 
Rosenthal N (2012) mIGF-1/JNK1/SirT1 signaling confers protection against oxidative stress 
in the heart. Aging Cell 11:139-149. 
50. Touvron M, Escoubet B, Mericskay M, Angelini A, Lamotte L, Santini MP, Rosenthal N, 
Daegelen D et al (2012) Locally expressed IGF1 propeptide improves mouse heart function 
in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent 
CTGF induction. Dis Model Mech 5:481-491. 
51. Musarò A, Mccullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, 
Sweeney HL et al (2001) Localized Igf-1 transgene expression sustains hypertrophy and 
regeneration in senescent skeletal muscle. Nat Gen 27:195-200. 
52. Lara-Pezzi E, Winn N, Paul A, Mccullagh K, Slominsky E, Santini MP, Mourkioti F, 
Sarathchandra P et al (2007) A naturally occurring calcineurin variant inhibits FoxO activity 
and enhances skeletal muscle regeneration. J Cell Biol 179:1205-1218. 
53. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson 
EN (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 
93:215-228. 
54. Woolard J, Bevan HS, Harper SJ, Bates DO (2009) Molecular diversity of VEGF-A as a 
regulator of its biological activity. Microcirculation 16:572-592. 
55. Carmeliet P, Ng Y-S, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, 
Kakkar VV et al (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in 
mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat 
Med 5:495-502. 
56. Zeng L, Xiao Q, Chen M, Margariti A, Martin D, Ivetic A, Xu H, Mason J et al (2013) 
Vascular endothelial cell growth–activated XBP1 splicing in endothelial cells is crucial for 
angiogenesis. Circulation 127:1712-1722. 
57. Thuerauf DJ, Marcinko M, Gude N, Rubio M, Sussman MA, Glembotski CC (2006) 
Activation of the unfolded protein response in infarcted mouse heart and hypoxic cultured 
cardiac myocytes. Circ Res 99:275-282. 
58. Hetz C, Glimcher L (2009) Fine-tuning of the unfolded protein response: assembling the 
IRE1 interactome. Mol Cell 35:551-561. 
59. Sawada T, Minamino T, Fu H, Asai M, Okuda K, Isomura T, Yamazaki S, Asano Y et al 
(2010) X-box binding protein 1 regulates brain natriuretic peptide through a novel AP1/CRE-
like element in cardiomyocytes. J Mol Cell Cardiol 48:1280-1289. 
60. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A et al 
(2009) Biodesign of a renal-protective peptide based on alternative splicing of B-type 
natriuretic peptide. Proc Natl Acad Sci USA 106:11282-11287. 
61. Zeng L, Zampetaki A, Margariti A, Pepe A, Alam S, Martin D, Xiao Q, Wang W et al 
(2009) Sustained activation of XBP1 splicing leads to endothelial apoptosis and 
atherosclerosis development in response to disturbed flow. Proc Natl Acad Sci USA 
106:8326-8331. 
62. Davis FJ, Gupta M, Pogwizd SM, Bacha E, Jeevanandam V, Gupta MP (2002) Increased 
expression of alternatively spliced dominant-negative isoform of SRF in human failing 
hearts. Am J Physiol Heart Circ Physiol 282:H1521-H1533. 
63. Creemers EE, Sutherland LB, Oh J, Barbosa AC, Olson EN (2006) Coactivation of MEF2 
by the SAP domain proteins myocardin and MASTR. Mol Cell 23:83-96. 
64. Zhu B, Ramachandran B, Gulick T (2005) Alternative pre-mRNA splicing governs 
expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors 
of striated muscle and brain. J Biol Chem 280:28749-28760. 
65. Debenedittis P, Jiao K (2011) Alternative splicing of T-box transcription factor genes. 
Biochem Biophys Res Commun 412:513-517. 
66. Georges R, Nemer G, Morin M, Lefebvre C, Nemer M (2008) Distinct expression and 
function of alternatively spliced Tbx5 isoforms in cell growth and differentiation. Mol Cell 
Biol 28:4052-4067. 
67. Fan C, Chen Q, Wang QK (2009) Functional role of transcriptional factor TBX5 in pre-
mRNA splicing and Holt-Oram syndrome via association with SC35. J Biol Chem 
284:25653-25663. 
68. Liao P, Yong TF, Liang MC, Yue DT, Soong TW (2005) Splicing for alternative 
structures of Cav1.2 Ca2+ channels in cardiac and smooth muscles. Cardiovasc Res 68:197-
203. 
69. Welling A, Ludwig A, Zimmer S, Klugbauer N, Flockerzi V, Hofmann F (1997) 
Alternatively spliced IS6 segments of the alpha 1C gene determine the tissue-specific 
dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2+ channels. 
Circ Res 81:526-532. 
70. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC, 
Keating MT (2005) Severe arrhythmia disorder caused by cardiac L-type calcium channel 
mutations. Proc Natl Acad Sci USA 102:8089-8096. 
71. Tang ZZ, Sharma S, Zheng S, Chawla G, Nikolic J, Black DL (2011) Regulation of the 
mutually exclusive exons 8a and 8 in the CaV1.2 calcium channel transcript by 
polypyrimidine tract-binding protein. J Biol Chem 286:10007-10016. 
72. George CH, Rogers SA, Bertrand BM, Tunwell RE, Thomas NL, Steele DS, Cox EV, 
Pepper C et al (2007) Alternative splicing of ryanodine receptors modulates cardiomyocyte 
Ca2+ signaling and susceptibility to apoptosis. Circ Res 100:874-883. 
73. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, Bauer EP, 
Klövekorn W-P et al (2003) Progression from compensated hypertrophy to failure in the 
pressure-overloaded human heart: structural deterioration and compensatory mechanisms. 
Circulation 107:984-991. 
74. Ding JH, Xu X, Yang D, Chu PH, Dalton ND, Ye Z, Yeakley JM, Cheng H et al (2004) 
Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart. EMBO J 
23:885-896. 
75. Feng Y, Valley MT, Lazar J, Yang AL, Bronson RT, Firestein S, Coetzee WA, Manley 
JL (2009) SRp38 regulates alternative splicing and is required for Ca
2+
 handling in the 
embryonic heart. Dev Cell 16:528-538. 
76. Ver Heyen M, Heymans S, Antoons G, Reed T, Periasamy M, Awede B, Lebacq J, 
Vangheluwe P et al (2001) Replacement of the muscle-specific sarcoplasmic reticulum 
Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild 
concentric hypertrophy and impairs contraction-relaxation of the heart. Circ Res 89:838-846. 
77. Shang LL, Pfahnl AE, Sanyal S, Jiao Z, Allen J, Banach K, Fahrenbach J, Weiss D et al 
(2007) Human heart failure is associated with abnormal C-terminal splicing variants in the 
cardiac sodium channel. Circ Res 101:1146-1154. 
78. Gao G, Xie A, Huang S-C, Zhou A, Zhang J, Herman AM, Ghassemzadeh S, Jeong E-M 
et al (2011) Role of RBM25/LUC7L3 in abnormal cardiac sodium channel splicing 
regulation in human heart failure. Circulation 124:1124-1131. 
79. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A et 
al (1998) Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. 
Nature 392:293-296. 
80. Zhang L, Vincent GM, Baralle M, Baralle FE, Anson BD, Benson DW, Whiting B, 
Timothy KW et al (2004) An intronic mutation causes long QT syndrome. J Am Coll Cardiol 
44:1283-1291. 
81. Murray A, Donger C, Fenske C, Spillman I, Richard P, Dong YB, Neyroud N, Chevalier 
P et al (1999) Splicing mutations in KCNQ1: a mutation hot spot at codon 344 that produces 
in frame transcripts. Circulation 100:1077-1084. 
82. Deschênes I, Disilvestre D, Juang GJ, Wu RC, An WF, Tomaselli GF (2002) Regulation 
of Kv4.3 current by KChIP2 splice variants: a component of native cardiac I(to)? Circulation 
106:423-429. 
83. Singh RK, Cooper TA (2012) Pre-mRNA splicing in disease and therapeutics. Trends 
Mol Med 18:472-482. 
84. Philips AV, Timchenko LT, Cooper TA (1998) Disruption of splicing regulated by a 
CUG-binding protein in myotonic dystrophy. Science 280:737-741. 
85. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum 
LPW (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. 
Science 293:864-867. 
86. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers 
AM, Hauswirth WW et al (2003) A muscleblind knockout model for myotonic dystrophy. 
Science 302:1978-1980. 
87. Ho TH, Bundman D, Armstrong DL, Cooper TA (2005) Transgenic mice expressing 
CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol 
Genet 14:1539-1547. 
88. Wang GS, Kearney DL, Biasi MD, Taffet G, Cooper TA (2007) Elevation of RNA-
binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of 
myotonic dystrophy. J Clin Invest 117:2802-2811. 
89. Kuyumcu-Martinez NM, Wang G-S, Cooper TA (2007) Increased steady-state levels of 
CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 
28:68-78. 
90. Wang G-S, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XHT, Cooper TA 
(2009) PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic 
dystrophy type 1. J Clin Invest 119:3797-3806. 
91. Savkur RS, Philips AV, Cooper TA (2001) Aberrant regulation of insulin receptor 
alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 
29:40-47. 
92. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, 
Thornton CA (2002) Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride 
channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 
10:35-44. 
93. Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA (2002) Loss of the 
muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated 
alternative splicing. Mol Cell 10:45-53. 
94. Yadava RS, Frenzel-Mccardell CD, Yu Q, Srinivasan V, Tucker AL, Puymirat J, 
Thornton CA, Prall OW et al (2008) RNA toxicity in myotonic muscular dystrophy induces 
NKX2-5 expression. Nat Genet 40:61-68. 
95. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins 
CM et al (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford 
progeria syndrome. Nature 423:293-298. 
96. Pendas AM, Zhou Z, Cadinanos J, Freije JMP, Wang J, Hultenby K, Astudillo A, 
Wernerson A et al (2002) Defective prelamin A processing and muscular and adipocyte 
alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 31:94-99. 
97. Lopez-Mejia IC, Vautrot V, De Toledo M, Behm-Ansmant I, Bourgeois CF, Navarro CL, 
Osorio FG, Freije JMP et al (2011) A conserved splicing mechanism of the LMNA gene 
controls premature aging. Hum Mol Genet 20:4540-4555. 
98. Scaffidi P, Misteli T (2006) Lamin A-dependent nuclear defects in human aging. Science 
312:1059-1063. 
99. Cao K, Blair CD, Faddah DA, Kieckhaefer JE, Olive M, Erdos MR, Nabel EG, Collins 
FS (2011) Progerin and telomere dysfunction collaborate to trigger cellular senescence in 
normal human fibroblasts. J Clin Invest 121:2833-2844. 
100. Osorio FG, Navarro CL, Cadiñanos J, López-Mejía IC, Quirós PM, Bartoli C, Rivera J, 
Tazi J et al (2011) Splicing-directed therapy in a new mouse model of human accelerated 
aging. Sci Transl Med 3:106ra107. 
101. Aartsma-Rus A (2012) Overview on AON Design. Methods Mol Biol 867:117-129. 
102. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA 
(2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat 
RNA. Science 325:336-339. 
103. Wheeler TM, Leger AJ, Pandey SK, Macleod AR, Nakamori M, Cheng SH, Wentworth 
BM, Bennett CF et al (2012) Targeting nuclear RNA for in vivo correction of myotonic 
dystrophy. Nature 488:111-115. 
104. Qi-Long Lu TY, Shin'ichi Takeda, Luis Garcia, Francesco Muntoni, and Terence 
Partridge (2011) The Status of Exon Skipping as a Therapeutic Approach to Duchenne 
Muscular Dystrophy. Mol Ther 19:9-15. 
105. Betts C, Saleh AF, Arzumanov AA, Hammond SM, Godfrey C, Coursindel T, Gait MJ, 
Wood MJA (2012) Pip6-PMO, A new generation of peptide-oligonucleotide conjugates with 
improved cardiac exon skipping activity for DMD treatment. Mol Ther Nucleic Acids 1:e38. 
106. Goemans NM, Tulinius M, Van Den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, 
Holling T, Janson AA et al (2011) Systemic administration of PRO051 in Duchenne's 
muscular dystrophy. N Engl J Med 364:1513-1522. 
107. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan J-C, Garcia L, Danos O 
(2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 
306:1796-1799. 
108. Scaffidi P MT (2005) Reversal of the cellular phenotype in the premature aging disease 
Hutchinson-Gilford progeria syndrome. Nat Med 11:440-445. 
109. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR (2011) 
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular 
atrophy mouse model. Nature 478:123-126. 
110. Spitali P, Aartsma-Rus A (2012) Splice modulating therapies for human disease. Cell 
148:1085-1088. 
111. Wang Z, Jeon HY, Rigo F, Bennett CF, Krainer AR (2012) Manipulation of PK-M 
mutually exclusive alternative splicing by antisense oligonucleotides. Open Biol 2. 
112. Zammarchi F, De Stanchina E, Bournazou E, Supakorndej T, Martires K, Riedel E, 
Corben AD, Bromberg JF et al (2011) Antitumorigenic potential of STAT3 alternative 
splicing modulation. Proc Natl Acad Sci USA 108:17779-17784. 
113. Sahashi K, Hua Y, Ling KKY, Hung G, Rigo F, Horev G, Katsuno M, Sobue G et al 
(2012) TSUNAMI: an antisense method to phenocopy splicing-associated diseases in 






Figure 1. Alternative splicing allows the expression of different proteins with distinct 
functional and structural features from a single gene. As the mRNA is being transcribed, 
introns are removed and exons are linked together by the spliceosome in a process known as 
splicing. Variations in the inclusion of exons, intron retention or the usage of an alternative 
splicing site give rise to proteins with different length, structure, localisation, regulation 
and/or function. 
 
Figure 2. Alternative splicing is controlled by cis-regulatory elements and trans-
regulatory factors. Splicing is carried out by a large ribonucleoprotein complex 
(spliceosome) comprised of more than 100 core proteins and five snRNAs (U1, U2, U4, U5 
and U6). Alternative splicing regulation is mediated by cis-regulatory sequences found in the 
spliced exon and in neighbouring introns. Cis-regulatory sequences can facilitate inclusion of 
an exon (splicing enhancers) or they can cause exon skipping (splicing silencers). Depending 
on their exonic or intronic position, splicing enhancers are known as ESE or ISE and splicing 
silencers are known as ESS or ISS. Most auxiliary cis-regulatory sequences act by recruiting 
trans-regulatory factors. In general, splicing enhancers bind SR proteins (Ser/Arg-rich SRSF 
factors), which facilitate spliceosome assembly, whereas splicing silencers recruit proteins of 
the hnRNP family, which can interfere with recruitment of the spliceosome or SR proteins. 
 
Figure 3. Alternative splicing regulates calcium handling and sarcomere contraction. 
The figure shows proteins involved in calcium mobilisation, cell signalling and sarcomere 
contraction that are regulated by alternative splicing, except for phospholamban. Calcium 
entry through the voltage-gated L-type calcium channels (LTCC) promotes calcium release 
from the sarcoplasmic reticulum through the ryanodine receptor (RyR). This promotes 
muscle contraction until calcium is pumped back into the sarcoplasmic reticulum by the 
SERCA2 ATPase. Calcium also activates calcineurin (Cn) and the calcium/calmodulin-
dependent protein kinase II (CaMKII), which modulate different processes in the 
cardiomyocyte. Some of the alternative splicing changes in the mRNAs encoding these 
proteins are associated with cardiomyopathies and heart failure, while others have a positive 
effect on the heart. 
 
Figure 4. Modulation of alternative splicing using antisense oligonucleotides as a 
therapeutic tool. A, Exon skipping of a mutated exon in the dystrophin gene (DMD) is 
promoted in Duchene muscular dystrophy to avoid premature truncation of the protein. 
Pathological splicing is indicated by a dashed line; the antisense oligonucleotide (AON) and 
the resulting corrected splicing are shown by thick lines; * indicates a mutation. B, Inhibition 
of an alternative splicing site due to a single mutation in Lamin A (LMNA) is blocked using 
AONs for the treatment of progeria. C, In myotonic dystrophy, a CUG expansion that 
sequesters MBNL1 in the DMPK and ZNF9 mRNAs is neutralised by AONs, allowing 
MBNL1 to reach its natural targets. D, Loss-of-function mutations in SMN1 cause spinal 
muscular atrophy. An AON targeting exon 7 in SMN2 promotes inclusion of the exon and the 
production of a functional SMN2 protein that partially compensates the loss of SMN1. 
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